The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated massive gains, the lapse of its patent opened the avenue to off-brand versions, dramatically reducing sales. This presents a particular challenge for pharmaceutical companies relying on similar blockbuster offerings, sugges

The story of Viagra, and its parent company copyright, presents a intriguing case study for investors. At first a blockbuster drug, generating billions in sales , its patent expiration created a deluge of knock-off medications, significantly eroding its dominance. While specific firms may seek to capitalize on male sexual dysfunction, the present l